CMS intends a significant drop in reimbursement for 340B drug payment program participants, along with potentially burdensome reporting requirements for non-participants. This article was originally ...
The federal 340B Drug Pricing Program, originally designed to maintain affordable medication access to patients who rely on safety-net clinics and hospitals, has continued to garner heightened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results